Patiromer and Diet/hrQoL in Chronic Dialysis

Summary

This is a phase III, prospective, randomized, double-blind, placebo-controlled, single-center, pilot trial, aimed at assessing whether treatment with the oral potassium binder patiromer as compared to placebo allows withdrawal or down-titration of potassium dietary restriction without increasing the risk of hyperkalemia in chronic dialysis patients.

Timeline

Start

2025-07-08

Primary completion

2026-07

Completion

2026-07

Drugs

Indications